Dr. Kaimakliotis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1701 N Senate Ave
Indianapolis, IN 46202Phone+1 317-948-6351Fax+1 317-944-0174
Education & Training
Yale-New Haven Medical CenterResidency, Urology, 2008 - 2012
Yale School of MedicineClass of 2007
Certifications & Licensure
IN State Medical License 2013 - 2025
CT State Medical License 2012 - 2013- American Board of Urology Urology
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.Phillip M Pierorazio, Nir Kleinmann, Ahmad Shabsigh, Brian Hu, Jay D Raman
The Journal of Urology. 2024-12-02 - Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark.Luopin Wang, Aryamav Pattnaik, Subhransu Sekhar Sahoo, Ella G Stone, Yuxin Zhuang
Nature Communications. 2024-08-24 - 3 citationsPerioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3...Mohamad E Allaf, Se-Eun Kim, Viraj Master, David F McDermott, Lauren C Harshman
The Lancet. Oncology. 2024-08-01
Authored Content
- Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
